The primary therapeutic role of Indigon (Metamizole/Dipyrone) is to provide symptomatic relief for specific presentations of intense discomfort and fever. Metamizole is commonly used to treat moderate-to-severe pain and fever in countries where it is authorized. It is generally applied in areas where short-term symptomatic assistance is needed to address pronounced symptoms that create noticeable physiological strain.

The core indications addressed by Indigon include severe systemic discomfort, acute episodes of visceral spasm and colic (such as renal or biliary pain), and persistent high fever (pyrexia). The medication supports the management of these conditions by easing distress and contributing to comfort during periods of heightened symptoms.

“Indigon is relevant when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.”

Quick Fact Block

Regulatory References

1. European Medicines Agency therapeutic overview

Who can and cannot use Indigon? — Official Regulatory Information

Indigon (indigotindisulfonate sodium) is a diagnostic dye indicated for use in adults to assess the integrity of the ureters following urological and gynecological surgical procedures. Eligibility is defined by specific exclusions and required cautions stated in regulatory documents.

Pregnancy and Lactation Status:

• Pregnancy: Available data have not identified a drug-associated risk of adverse fetal effects over several decades; however, data are insufficient to evaluate risk during the first trimester. Use only if clearly needed.
• Lactation: Transfer into breast milk is likely to be low, and adverse effects on the breastfed infant are not expected.

Regulatory information establishes that use is strictly limited to non-allergic adults with adequate kidney function, with specific cautions mandated for those with pre-existing heart conditions.

Interactions with other medicines and products

Official regulatory documents indicate that this product, chemically Indigotindisulfonate Sodium, has no documented moderate or minor drug-drug interactions with other medicinal products. The documented interactions primarily involve pre-existing medical conditions and interference with medical devices, rather than a pharmacokinetic effect on co-administered drugs.

Clinical and Diagnostic Interactions

Interaction Implications

Co-administration with medicines that cause bradycardia or in patients with pre-existing cardiovascular disorders may place the patient at increased risk for adverse effects, including both elevated blood pressure and severe hypotension. The official labeling mandates close monitoring of blood pressure and cardiac rhythm during and following administration in these patient populations.

Furthermore, the blue color of the product is known to interfere with the absorption of light used in certain medical devices. Specifically, a transient, artifactual reduction in pulse oximetry readings (SpO₂) may occur. Awareness of this potential interference is required by the official labeling to prevent misinterpretation of vital signs during the procedure. The documented interaction profile is highly procedural and condition-based, reflecting its use as a diagnostic visualization aid.

Indigon, specifically its active components such as indirubin and indigo, exerts its systemic modulation through multiple intracellular pathways. Primarily, indirubin acts as an inhibitor of various protein kinases, including the Janus kinase 3 (JAK3) and the signal transducer and activator of transcription 3 (STAT3) pathway, thus mitigating the downstream cascade of pro-inflammatory transcription. Separately, both indirubin and indigo function as agonists for the Aryl Hydrocarbon Receptor (AhR), which is expressed highly in the intestinal epithelium. Activation of AhR upregulates the transcription of metabolic enzymes like CYP1A1, a consequence that contributes to systemic anti-inflammatory signaling. Furthermore, Indigon components suppress the Toll-like Receptor 4 (TLR4)/MyD88/NF-kappaB signaling axis, diminishing the activation of the nuclear factor-kappaB transcription factor. This suppression reduces the intracellular generation and secretion of pro-inflammatory cytokines, resulting in the systemic reduction of inflammatory cellular infiltration and activity.

How to Use Indigon

The general principle of using Indigon (Metamizole/Dipyrone) is to provide short-term, symptomatic relief based on the intensity of symptoms, following a strict intermittent schedule. Administration is restricted to the lowest dose necessary to manage acute symptoms, adhering strictly to established limits.

Official Administration Guidelines

Procedural and Population-Specific Use

Administration of the injectable form requires specific procedural adherence: the intravenous injection must be administered very slowly. For patients requiring dilution, mixtures must be used immediately after preparation to ensure proper use.

Specific dosing rules apply to certain populations. A reduced dose is specified for older adults and debilitated patients due to a prolonged elimination rate of the active metabolites. In cases of severe hepatic or renal impairment, multiple high doses must be avoided as a general measure, although short-term use may not require a specific dose reduction.

Research evidence / Overview of studies for Indigon

The research evidence for Indigon (Metamizole/Dipyrone) is derived from numerous clinical studies that focus on how patients reported their experience during acute episodes of pain and fever. This overview describes the research that has been conducted and what the findings generally indicate, while adhering strictly to non-causal and neutral descriptions of study structures.

Evidence for Use in Acute Severe Pain

Research has primarily involved short-term, randomized controlled trials (RCTs) that compared Indigon against an inactive substance (placebo) or an active comparator. These studies were applied in research contexts involving episodes of heightened symptom activity, particularly in adult populations following surgical procedures. Studies monitored outcomes related to physical discomfort, such as the time it took for patients to register a change in pain intensity and the need for additional pain medication (rescue analgesia).

It is not yet clear how these findings apply to chronic, ongoing pain. Long-term outcomes for repeated use in non-acute settings are not well characterized in the high-quality trial literature.

Evidence for Managing Visceral Spasms and Colic

Indigon was studied for conditions involving periods of heightened symptoms related to involuntary muscle spasm, particularly the acute, disruptive episodes of renal or biliary colic. Studies explored outcomes linked to episodic or acute changes, such as the measured reduction in spasm-related pain intensity. Study designs primarily focused on patient-reported outcomes over very short observation periods. Sample sizes were modest in some of the older trials, and reliance on a small number of large-scale RCTs means that certainty remains low regarding broad comparisons across all possible colic-related conditions.

Evidence for Reducing Persistent High Fever

Indigon was evaluated in numerous comparative RCTs and subsequent systematic reviews to explore how it was observed in managing persistent high fever (pyrexia) in both children and adults. Research monitored outcomes related to systemic or functional imbalance, such as the speed and magnitude of the temperature change. Research describes patterns of temperature change when compared to other non-opioid agents.

What is Still Uncertain About Indigon's Research

The overall evidence base, while extensive for acute pain and fever, includes several recognized limitations: Follow-up durations were limited (predominantly short-term), meaning there is limited information for chronic or repeated use. Additionally, data for certain groups remain insufficient, particularly for older adults or patients with complex pre-existing conditions.

Key Studies & References

1. Effectiveness of dipyrone (metamizole) in postoperative analgesia: A systematic review and meta-analysis

Common questions about Indigon (FAQ)

Q: What is the difference between Indigon and other similar treatments?

Official documents describe Indigon’s primary purpose as a diagnostic visualization aid. This means it is a blue dye used by surgeons to help confirm the integrity of the ureters (tubes that carry urine from the kidneys to the bladder) during specific urological or gynecological procedures. It is classified as a diagnostic agent, not a medicine intended to treat symptoms or disease.

Q: How quickly does Indigon start working after I take it?

Indigon is administered by a healthcare professional as an intravenous injection during a procedure. According to official product information, the visual effect (the appearance of the blue color) is typically detectable at the ureteral orifices within 4 to 9 minutes after the injection.

Q: How does Indigon affect the kidneys or liver?

Regulatory documents advise not recommending use of Indigon in patients who have severe kidney impairment, specifically those with an eGFR (a measure of kidney function) below 30 mL/min. The official labeling also notes that elevated ALT levels were a common adverse reaction (1–10%) reported in clinical trials.

Q: What happens if I take Indigon with alcohol?

The official documentation on Indigon’s drug-drug interaction profile indicates that it has no noted moderate or minor interactions with other medicinal products. Because of this, no specific warnings regarding alcohol consumption are listed in the official labeling.

Q: Is Indigon new or has it been around for a while?

While the active ingredient, Indigotindisulfonate Sodium, has been used for some time, the current FDA-approved drug product (sold under the brand name Bludigo) received its New Drug Approval (NDA) on July 8, 2022. This approval pertains to the specific formulation and use of the diagnostic dye.

Q: Does Indigon cure the condition or just manage the symptoms?

Indigon is not used as a treatment and does not cure any condition or manage symptoms. It is specifically classified as a diagnostic dye and is used only as a visualization aid by surgeons during specific procedures.

Q: What is the longest I can expect to take Indigon?

Indigon is administered by a healthcare professional as a single intravenous injection during a surgical procedure. It is not intended for repeated use or ongoing therapy.

Q: Can Indigon interact with over-the-counter medications like ibuprofen?

Official documents state that Indigon has no noted moderate or minor drug-drug interactions with other medicinal products. This suggests that it is not expected to interfere chemically with over-the-counter medications like ibuprofen.

Q: Is Indigon appropriate for children?

The official regulatory documentation clearly states that the safety and effectiveness of Indigon have not been established in pediatric patients.

Q: Is there an age limit for who can use Indigon?

Official information indicates that Indigon is indicated for use in adults to assess the integrity of the ureters following surgical procedures. Its use is not established for anyone in the pediatric age group.

Q: Will Indigon show up on a standard drug test?

Indigon is not classified as a controlled substance and is not listed in any Drug Enforcement Administration (DEA) schedules. Its profile is that of a diagnostic dye.

Q: Is there a generic version of Indigon available?

The active ingredient in Indigon is indigotindisulfonate sodium, which is the generic name of the drug.

Q: Why do some people say they need to stop taking Indigon?

Official warnings require the administration of Indigon to be interrupted if a patient exhibits signs of specific severe reactions. These reactions include cardiovascular issues, such as changes in heart rhythm or blood pressure, or signs of anaphylaxis (a severe allergic reaction).

Q: Does Indigon need to be taken with food?

No. Indigon is administered by a healthcare professional as an intravenous injection and is not a medication that is taken orally with food.

Q: Can Indigon cause stomach upset?

Official reports indicate that common adverse reactions (occurring in 1% or more of patients) reported in clinical trials include gastrointestinal effects such as nausea, vomiting, abdominal pain, and constipation.

Q: Are there any specific foods I should avoid while taking Indigon?

Official documents indicate that Indigon has no noted moderate or minor drug-drug interactions with other medicinal products. Because it is a single-use diagnostic dye, there are no warnings about specific foods listed in the official labeling.

Q: Why does the packaging say Indigon should be used for short-term treatment?

Indigon is not a treatment and is not intended for any long-term use. Its only purpose is as a visualization aid during a single surgical procedure, and its function is completed quickly after administration.

Q: What kind of research studies were done on Indigon?

Official approval documents are based on clinical trials focused on assessing the dye's primary function: its use as a visualization aid for checking the integrity of the ureters during specific surgical procedures.

Q: Is Indigon addictive?

Indigon is a diagnostic dye that is not a controlled substance. Its use is not known to lead to dependence or abuse, according to the drug's official profile.

Q: Can Indigon be used to treat anxiety (if not an approved use)?

Indigon is indicated only for use as a diagnostic dye to assist surgeons in visualizing the integrity of the ureters during specific surgical procedures. It is not approved for any treatment purposes, including anxiety.

Q: Is Indigon available in different strengths?

The drug is standardized for its specific use. The recommended dose of Indigon is a single 5 mL intravenous injection, and the drug product is standardized for this volume and concentration.

Q: Is Indigon ever used in combination with other drugs?

The official administration instructions strictly state that Indigon must not be administered using the same intravenous infusion assemblies that have been used with other diluents or drugs.

How to Store and Dispose of Indigon (Metamizole/Dipyrone)

The official labeling outlines specific storage and disposal requirements to maintain product integrity and ensure safety.

Storage Conditions

Indigon must be stored at or below 25 C or 30 C (room temperature) and should not be refrigerated or frozen. The medicine requires protection from light and moisture, necessitating storage in the original container with the container tightly closed where applicable. All formulations must be kept strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Indigon must be disposed of according to local regulatory requirements for pharmaceutical waste, such as authorized drug take-back programs. The product must not be disposed of in wastewater or released into the environment due to regulatory warnings about potential aquatic toxicity. Any unused portion of a single-dose injection must be immediately discarded.